Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients

Transplantation

Volumn 81, Issue 5, 2006, Pages 711-717

  Hibberd, Adrian D ^a,b,e   Trevillian, Paul R ^a,b   Roger, Simon D ^c   Wlodarczyk, John H ^d   Stein, Ann M ^a   Bohringer, Elizabeth G ^c   Milson Hawke, Sally M ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Renal Research   (Australia)

^d John Wlodarczyk Consulting Services   (Australia)

^e Newcastle Transplant Unit   (Australia)

Author keywords

Cyclosporine A; Generic; Randomized controlled trial

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYSPORIN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; FEMALE; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; STATISTICAL ANALYSIS;

ADULT; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUGS, GENERIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 33645050694     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000181198.98232.0c     Document Type: Article

References (40)

1. Wolfe RA, Ashby VB, Milford EF, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 431: 1725.
2. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost utility of renal transplantation. Kidney Int 1996; 50: 235.
3. Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation - a prospective study. Transplantation 1992; 54: 656.
4. Starzl TE, Murase N, Abu Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
5. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation; analysis at three years. N Engl J Med 1986; 314: 1219.
6. Christians U, First RM, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit 2000; 22: 330.
7. Pollard S, Nashan B, Johnston A, et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of Cyclosporin A. Clin Ther 2003; 25: 1654.
8. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003; 3: 1211.
9. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation-a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658.
10. Lindholm A, Jahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205.
11. Kahan BD, Welch M, Schoenberg L, et al. Variable oral absorption of Cyclosporine. A pharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599.
12. Barr WH. Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets. Transplant Proc 1999; 31: 25S.
13. Kahan BD, Welsh M, Rutsky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995; 17: 621.
14. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation; a prospective study. J Am Soc Nephrol 2001; 12: 823.
15. Shah MB, Martin JE, Schroeder TJ, et al. The evaluation of the safety and tolerability of two formulations of cyclosporine: Neoral and Sand-immune. A meta-analysis. Transplantation 1999; 67: 1411.
16. Otto MG, Mayer AD, Clavien PA, et al. Randomized trial of cyclosporine microemulsion (Neoral) versus conventional cyclosporine in liver transplantation. Transplantation 1998; 66: 1632.
17. Food and Drug Administration (FDA). Bioavailability and bioequivalence requirements. Fed Regis 1992; 57: 17997.
18. CPMP (Committee for Proprietary Medicinal Products) Working Party in the Efficacy of Medicinal Products. Note for guidance: Investigation of bioavailability and bioequivalence. The Rule Governing Medicinal Products in the European Community 1991; 3: 149.
19. Birkett DJ. Generics-equal or not? Aust Prescriber 2003; 26: 85.
20. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
21. R Development Core Team (2004). R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria. Available at: http://www.R-project.org. Accessed 24 February 2005.
22. SAS (2004) version 9.1.2, SAS Institute Inc., Cary, NC.
23. Hintze J. NCSS and PASS, Number cruncher statistical systems, Kaysville, Utah. Available at: www.ncss.com. Accessed 24 February 2005.
24. Johnston A, Keown PA, Holt DW. Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit 1997; 19: 375.
25. David-Neto E, Kakehashi E, Alves CF, et al. Bioequivalence of a new cyclosporine A formulation to Neoral. Ther Drug Monit 2004; 26: 53.
26. Kim SC, Han DJ. Neoplanta as a new microemulsion formula of cyclosporine in renal transplantation: comparative study with Neoral for efficacy and safety. Transplant Proc 1998; 30: 3547.
27. Curtis JJ, Barbeito R, Pirsch J, et al. Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients. Am J Kidney Dis 1999; 34: 869.
28. Sinescu I, Vasconcellos Lopes HV, Foschi D, et al. New cyclosporine microemulsion randomized cross-over bioequivalence steady-state study in renal transplant patients. Eur Rev Med Pharmacol Sci 1999; 3: 11.
29. Park MS, Yu NC, Kim YS, et al. Bioequivalence study of Cipol-N (cyclosporine microemulsion preparation) in healthy adults. Transplant Proc 1998; 30: 3541.
30. Rosa A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002; 74: 1013.
31. Takaulikur GS, Gallagher MP, Carney GM, et al. Switchover to generic cyclosporine in stable renal transplant recipients: a single unit experience. Nephrology 2004; 9: 418.
32. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 55.
33. Keown P, Cole E, Miurhead N, et al. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
34. 2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003; 76: 1236.
35. Durlik M, Rauch C, Throff-Friesinger U, et al. Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations. Transplant Proc 2003; 35: 1304.
36. Pollard SG, Lear PA, Ready AR, et al., for the UK Neoral Renal Study Group. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. Transplantation 1999; 68: 1325.
37. Eisen H, Hobbs RE, Davis SF, et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicentre, double-blind comparison with the oil based formulation of cyclosporine - results at six months after transplantation. Transplantation 1999; 68: 663.
38. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481.
39. Talaulikar GS, John GT, Selvakumar R, et al. Pre and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. Transplant Proc 2003; 35: 1295.
40. CTS Collaborative Study. Newsletter 1: 2001. Available at: http://www. ctstransplant.org/public/literature/newsletters/2001/gif/2001-1.html. Accessed 13 February 2005.